Wyeth's transdermal nitroglycerin
Executive SummaryFDA conditionally approved Wyeth's transdermal delivery system, trademarked Deponit 5 and Deponit 10, May 6. The product is available in dosages of 5 mg/24 hours and 10 mg/24 hours. Wyeth is the fifth firm to enter the transdermal nitroglycerin market. Bolar, Ciba-Geigy, Searle and Key Pharmaceuticals already market transdermal nitroglycerin.
You may also be interested in...
FDA’s food, dietary supplement and cosmetics division seeks funding to support its artificial intelligence capabilities, including post-market surveillance and speedy interventions in instances where safety issues arise. Also of note, the agency cites UV filters’ effects on the skin microbiome as a research priority in its fiscal 2021 budget justification to Congress.
Catering to patients can help make clinical trials more accessible and useful, presenters argued at a recent conference.
In separate warning letters, the US FDA says Biomedix (a maker of I.V. administration sets) and Unetixs Vascular (a maker of vascular diagnostic ultrasound systems) must hire outside consultants to review their quality systems after serious deficiencies were noted by agency investigators. A total of three enforcement missives were released by the FDA this week.